Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol (2005) 1.88

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg (2016) 1.55

Tissue penetration of antifungal agents. Clin Microbiol Rev (2014) 1.13

Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother (2012) 1.09

Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol (2006) 1.01

Approaches using molecular imaging technology -- use of PET in clinical microdose studies. Adv Drug Deliv Rev (2010) 0.97

Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother (2012) 0.96

Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J (2006) 0.96

PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab (2011) 0.95

Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci U S A (2013) 0.93

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93

Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.92

Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother (2005) 0.91

Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem (2010) 0.90

Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance. Proc Natl Acad Sci U S A (2015) 0.89

Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother (2006) 0.89

Human tissue distribution of voriconazole. Antimicrob Agents Chemother (2010) 0.84

Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother (2009) 0.84

Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol (2014) 0.84

Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob Agents Chemother (2012) 0.83

A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. Clin Pharmacokinet (2011) 0.83

Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. Antimicrob Agents Chemother (2008) 0.83

Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS One (2014) 0.83

Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging. Antimicrob Agents Chemother (2015) 0.82

Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype. Antimicrob Agents Chemother (2010) 0.82

[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrob Agents Chemother (2004) 0.82

Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry. Proteomics (2016) 0.81

Antimicrobial-induced DNA damage and genomic instability in microbial pathogens. PLoS Pathog (2015) 0.80

Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother (2011) 0.80

Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget (2015) 0.80

Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics. Drug Deliv (2015) 0.80

Radiosynthesis and biological evaluation of a novel enoyl-ACP reductase inhibitor for Staphylococcus aureus. Eur J Med Chem (2014) 0.78

Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist (2014) 0.77

Beyond conventional antibiotics - New directions for combination products to combat biofilm. Adv Drug Deliv Rev (2016) 0.77

Enantiomeric radiochemical synthesis of R and S (1-(6-amino-9H-purin-9-yl)-3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA). J Labelled Comp Radiopharm (2008) 0.77

Pharmacokinetic study on pradofloxacin in the dog - comparison of serum analysis, ultrafiltration and tissue sampling after oral administration. BMC Vet Res (2013) 0.77

In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. Antimicrob Agents Chemother (2015) 0.76

Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase. Bioorg Med Chem Lett (2015) 0.75

Pharmacodynamic variability beyond that explained by MICs. Antimicrob Agents Chemother (2013) 0.75

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques. Antimicrob Agents Chemother (2017) 0.75

Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier. J Control Release (2015) 0.75

Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). Infect Dis Ther (2014) 0.75

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol (2017) 0.75

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest (1995) 3.13

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66

The next frontier of molecular medicine: delivery of therapeutics. Nat Med (1998) 2.59

Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis (1981) 2.54

Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci (1973) 2.45

Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother (1983) 2.42

Penetration of antibiotics into fibrin loci in vivo. I. Comparison of penetration of ampicillin into fibrin clots, abscesses, and "interstitial fluid". J Infect Dis (1974) 2.20

Microdialysis--principles and applications for studies in animals and man. J Intern Med (1991) 2.17

PET: the merging of biology and imaging into molecular imaging. J Nucl Med (2000) 2.15

Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet (1994) 2.07

Tissue-directed pharmacokinetics. Am J Med (1991) 2.00

Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet (1977) 1.96

Bacterial resistance to fluoroquinolones. Rev Infect Dis (1988) 1.91

Penetration of antibiotics into respiratory secretions. Rev Infect Dis (1981) 1.86

Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother (1996) 1.83

Application of microdialysis in pharmacokinetic studies. Pharm Res (1997) 1.74

Filtration coefficients and osmotic reflexion coefficients of the walls of single frog mesenteric capillaries. J Physiol (1980) 1.70

The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet (1987) 1.66

Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother (1999) 1.54

Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother (1993) 1.52

Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med (2001) 1.50

Multiple pathways of capillary permeability. Circ Res (1977) 1.50

Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther (2002) 1.46

Intravitreal penetration of teicoplanin. Eye (Lond) (1998) 1.45

Drug distribution studies with microdialysis. III: Extracellular concentration of caffeine in adipose tissue in man. Life Sci (1991) 1.44

Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther (1995) 1.44

Antibiotic treatment failures in acute otitis media. Pediatr Ann (1991) 1.42

Penetration of antibiotics into the normal and diseased maxillary sinus mucosa. Scand J Infect Dis Suppl (1978) 1.39

Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med (1976) 1.39

Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother (1998) 1.37

Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol (2001) 1.34

A review of the penetration of antibiotics into CSF and its clinical significance. Scand J Infect Dis Suppl (1978) 1.33

Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am (1989) 1.30

Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. II. Studies in man. J Antimicrob Chemother (1983) 1.26

Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother (2000) 1.19

19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev (2000) 1.19

Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res (1993) 1.18

Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis (1995) 1.16

Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med (2000) 1.16

Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother (1999) 1.15

5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res (1997) 1.13

Clinical significance of tissue penetration of antibiotics in the respiratory tract. Scand J Infect Dis Suppl (1978) 1.13

Prostatitis: Man's hidden infection. Urol Clin North Am (1975) 1.09

Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother (1993) 1.05

Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis (1988) 1.05

Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother (1999) 1.04

Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol (2000) 1.04

Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet (1998) 1.04

Antibiotics in bone tissues. Methodological and practical aspects. Scand J Infect Dis Suppl (1978) 1.03

Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis (1993) 1.03

Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother (1993) 1.03

Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol (1997) 1.02

Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res (2001) 1.02

Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet (1982) 1.01

Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev (2000) 1.01

The penetration of anti-infectives into the central nervous system. Neurol Clin (1999) 1.01

Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob Agents Chemother (1991) 1.01

Determinants of capillary permeability: a review of mechanisms based on single capillary studies in the frog. Circ Res (1986) 1.00

Microdialysis of adipose tissue and blood for in vivo lipolysis studies. Am J Physiol (1988) 1.00

A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99

Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res (1996) 0.99

Non-invasive radiotracer imaging as a tool for drug development. Curr Pharm Des (2000) 0.99

Pharmacodynamics of antibiotics in fibrin clots. J Antimicrob Chemother (1993) 0.98

Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther (1993) 0.98

In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. Clin Pharmacol Ther (1990) 0.98

Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis. J Antimicrob Chemother (1998) 0.98

Comparison of three different experimental methods for the assessment of peripheral compartment pharmacokinetics in humans. Life Sci (1998) 0.98

Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scand J Infect Dis Suppl (1978) 0.98

Analysis of ceftriaxone and ceftazidime distribution in cerebrospinal fluid of and cerebral extracellular space in awake rats by in vivo microdialysis. Antimicrob Agents Chemother (1995) 0.97

Comparison of plasma and free tissue levels of ceftriaxone in rats by microdialysis. J Pharm Sci (1997) 0.97

Clinical applications: MRI, SPECT, and PET. Magn Reson Imaging (1995) 0.95

Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother (2003) 0.95

A comparison of the pharmacokinetics in serum and nasal secretions after oral bacampicillin and ampicillin. Scand J Infect Dis Suppl (1978) 0.95

Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother (1994) 0.95

Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med (2002) 0.94

Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in rats, studied by microdialysis. Antimicrob Agents Chemother (1992) 0.93

Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther (2001) 0.93

The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev (1997) 0.92

Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. Toxicol Appl Pharmacol (1997) 0.92

Determination of free extracellular concentrations of piperacillin by microdialysis. J Pharm Sci (1996) 0.92

Methods for evaluating the penetration of beta-lactam antibiotics into tissues. Rev Infect Dis (1986) 0.92

Microdialysis study of zidovudine (AZT) transport in rat brain. J Pharmacol Exp Ther (1993) 0.90

Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neurology (1994) 0.90

Absorption of bacampicillin and ampicillin and penetration into body fluids (skin blister fluid, saliva, tears) in healthy volunteers. Scand J Infect Dis Suppl (1978) 0.90

Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem (2002) 0.90

In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: penetration of chloramphenicol from lipophilic vehicles and a nail lacquer. J Pharm Pharmacol (1997) 0.90

Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, in vivo microdialysis and saliva sampling. Br J Clin Pharmacol (1998) 0.89

Pharmacokinetic study of beta-lactam antibiotics in bronchial secretions. Scand J Infect Dis Suppl (1978) 0.89

Physics and instrumentation for imaging in-vivo drug distribution. Adv Drug Deliv Rev (2000) 0.88

Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Dispos (1997) 0.88

Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. Acta Derm Venereol (1999) 0.87

Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J Pharmacol Toxicol Methods (1993) 0.86

Pharmacokinetic evaluation of beta-lactam antibiotics. J Antimicrob Chemother (1989) 0.86

An application of microdialysis to drug tissue distribution study: in vivo evidence for free-ligand hypothesis and tissue binding of beta-lactam antibiotics in interstitial fluids. J Pharmacobiodyn (1992) 0.86

Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis. Pharm Res (1996) 0.86

Factors affecting solubility and penetration of clarithromycin through gastric mucus. Aliment Pharmacol Ther (1998) 0.86

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm Res (1997) 0.85

Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci (1995) 0.85

Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. J Ocul Pharmacol Ther (1996) 0.85

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50

Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10

Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92

Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46

PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38

Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37

How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37

AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35

Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34

Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem (2006) 1.26

Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24

Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23

Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20

Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16

Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14

Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13

Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12

Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11

Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11

Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10

Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09

Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am (2005) 1.07

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol (2004) 1.07

Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci (2002) 1.06

Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol (2003) 1.05

Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine (2002) 1.04

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents (2012) 1.03

Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents (2010) 1.03

Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol (2003) 1.02

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents (2005) 1.02

Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. J Agric Food Chem (2008) 1.01

Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents (2009) 1.01

AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01

Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99

In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother (2009) 0.98

Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol (2010) 0.98

PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol (2008) 0.98

Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother (2007) 0.98

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol (2013) 0.98

Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol (2011) 0.97

Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv (2011) 0.97

Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet (2009) 0.96

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol (2004) 0.96

Clinical microdialysis in skin and soft tissues: an update. J Clin Pharmacol (2008) 0.96

Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94

Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol (2010) 0.94

Interstitial tissue concentrations of cefpodoxime. J Antimicrob Chemother (2002) 0.93

How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc (2004) 0.93

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res (2010) 0.93

The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence. Microbiology (2008) 0.93

Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels. J Clin Pharmacol (2013) 0.93

Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem (2006) 0.93

A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro. Int J Antimicrob Agents (2008) 0.92

Single- and multiple-dose pharmacokinetics of oral creatine. J Clin Pharmacol (2003) 0.91

Physiological, pharmacokinetic, and pharmacodynamic changes in space. J Clin Pharmacol (2004) 0.91

Grapefruit-medication interactions. CMAJ (2013) 0.91

Antimicrobial tissue concentrations. Infect Dis Clin North Am (2003) 0.91

Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother (2006) 0.90

Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents (2009) 0.89

Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol (2005) 0.88

Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography. Antimicrob Agents Chemother (2007) 0.88

Systemic availability and pharmacokinetics of thymol in humans. J Clin Pharmacol (2002) 0.87

Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci (2010) 0.87

Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn (2013) 0.86

Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents (2009) 0.85

Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.85

Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats. Pharmacol Biochem Behav (2010) 0.85

Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother (2009) 0.85

Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents (2008) 0.85

Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn (2006) 0.84

Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol (2005) 0.84

Pharmacokinetics of valerenic acid in rats after intravenous and oral administrations. Planta Med (2012) 0.84

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Ther Clin Risk Manag (2010) 0.83

Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci (2005) 0.83

Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Clin Pharmacol (2010) 0.83

Model-based drug approval - the rubber hits the road. Int J Clin Pharmacol Ther (2012) 0.82

Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci (2007) 0.81

Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.81

In vitro microdialysis sampling of docetaxel. J Pharm Biomed Anal (2004) 0.81

Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone. AAPS J (2008) 0.81

Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Chest (2008) 0.81

Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol (2003) 0.81

When is protein binding important? J Pharm Sci (2013) 0.81

Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis. Antimicrob Agents Chemother (2013) 0.81

Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med (2004) 0.81

A novel breath test to directly measure use of vaginal gel and condoms. AIDS Behav (2013) 0.80

Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily. Antimicrob Agents Chemother (2013) 0.80

Pharmacokinetic properties of pure xanthones in comparison to a mangosteen fruit extract in rats. Planta Med (2013) 0.80

Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans. J Clin Pharmacol (2002) 0.79

Pharmacokinetics and tissue distribution of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides after oral administration in rats. Planta Med (2009) 0.79

Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentration versus time-kill curves. Expert Opin Drug Discov (2007) 0.79

Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. J Clin Pharmacol (2002) 0.79

Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol. J Clin Pharmacol (2004) 0.79

Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Neuropharmacology (2008) 0.78

Predicting pediatric age-matched weight and body mass index. AAPS J (2014) 0.78

Determination of atypical nonlinear plasma−protein-binding behavior of tigecycline using an in vitro microdialysis technique. J Pharm Sci (2014) 0.78

Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs. Biopharm Drug Dispos (2008) 0.78

Microdialysis as a tool in local pharmacodynamics. AAPS J (2006) 0.78